Competitor Analysis: Wnt Pathway Inhibitors
Product description
Wnt proteins are secreted glycoproteins acting as short or long range signaling molecules. To trigger a cellular response and to activate intracellular signal transduction, they bind to receptors of the Frizzled family and several co-receptors such as lipoprotein receptor-related protein (LRP)-5/6, Ryk, or Ror2.
The present Competitive Intelligence report about Wnt Pathway Inhibitors provides a competitor evaluation in the field of small molecule-, antibody- and peptide-based inhibitors of Wnt and its receptors for the treatment of cancer as of September 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of small molecule, peptide and antibody inhibitors of the Wnt ligand or its receptors Frizzled and LRP5/6 in oncology. In addition, the report lists company-specific R&D pipelines of Wnt pathway inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Wnt proteins are secreted glycoproteins acting as short or long range signaling molecules. To trigger a cellular response and to activate intracellular signal transduction, they bind to receptors of the Frizzled family and several co-receptors such as lipoprotein receptor-related protein (LRP)-5/6, Ryk, or Ror2.
The present Competitive Intelligence report about Wnt Pathway Inhibitors provides a competitor evaluation in the field of small molecule-, antibody- and peptide-based inhibitors of Wnt and its receptors for the treatment of cancer as of September 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of small molecule, peptide and antibody inhibitors of the Wnt ligand or its receptors Frizzled and LRP5/6 in oncology. In addition, the report lists company-specific R&D pipelines of Wnt pathway inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage
- Additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- Wnt Pathway Inhibitors in Oncology
- Corporate Wnt Pathway Inhibitor R&D Pipelines
